97 completed, 11 unknown, 6 recruiting, 6 terminated. 42 Phase 2, 37 Phase 4, 20 Phase 3, 16 Phase 1, 10 Not applicable.
Follow Atomoxetine: new trials by email Literature Review of Atomoxetine trials Research Report on Atomoxetine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Atomoxetine in Melanocortin Obesity Syndrome Atomoxetine, Placebo - Melanocortin Obesity Syndrome, MCOS | Phase 2 | Recruiting | Icahn School of Medicine at Mount Sinai | 20 | 2026-09-01 | 2026-08-07 |
| Study of the Effects of Atomoxetine on Motivation Atomoxetine, Placebo - Apathy | Phase 4 | Not yet recruiting | University of Oxford | 40 | 2026-08-01 | 2026-08-18 |
| An Evaluation of Treatments for Sustained Clinical Response (18 Months) in Symptomatic Alzheimer's Disease Placebo, Atomoxetine, Metformin 1000 mg Oral Tablet - Alzheimer's Disease (AD), Mild Cognitive Impairment Due to Alzheimer's Disease | Phase 3 | Recruiting | University College, London | 1200 | 2026-07-24 | 2026-07-23 |
| Atomoxetine and Executive Function in PTSD Atomoxetine, Placebo - Posttraumatic Stress Disorder With Attention Defic | Phase 4 | Recruiting | VA Office of Research and Development | 160 | 2026-04-01 | 2026-07-07 |
| Pharmacologically Modulating the Noradrenergic Arousal System to Reduce Freezing of Gait in Parkinson's Disease: a Multi-centre and Multi-modal Approach Atomoxetine, Placebo - Parkinson's Disease (PD), Freezing of Gait | Phase 3 | Recruiting | Radboud University Medical Center | 60 | 2026-01-01 | 2026-02-27 |
| Role of the Noradrenergic System in the Regulation of Learning Dynamics: Evaluation of the Effect of a Low-dose Selective Noradrenaline Reuptake Inhibitor (NOISYXETINE) Atomoxetine, Placebo - Role of the Noradrenergic System in the Regulation of Learning Dynamics, No Disease or Condition is Being Studied | Not applicable | Recruiting | Centre Hospitalier St Anne | 160 | 2025-11-18 | 2025-11-20 |
| Evaluating the Efficacy of Atomoxetine in Reducing Primary Nocturnal Enuresis in Children With ADHD: A Randomized, Placebo-Controlled Study Atomoxetine, Placebo - ADHD, Primary Nocturnal Enuresis | Early Phase 1 | Not yet recruiting | Tanta University | 100 | 2025-02-28 | 2025-02-27 |
| Black Seed Oil in ADHD Atomoxetine, Black Seed Oil Cap/Tab - ADHD | Phase 2 | Unknown | Ain Shams University | 60 | 2024-10-01 | 2024-08-09 |
| Pharyngeal Muscle Control Mechanisms of Atomoxetine-plus-oxybutynin in Obstructive Sleep Apnea Atomoxetine 80 mg plus Oxybutynin 5 mg, Atomoxetine 80 MG, Placebo - OSA | Phase 1 / Phase 2 | Completed | Brigham and Women's Hospital | 27 | 2023-12-01 | 2025-12-17 |
| Atomoxetine in Patients With Tourette's Syndrome Atomoxetine - Tourette Syndrome | Phase 2 | Terminated | Poitiers University Hospital | 5 | 2022-05-31 | 2024-01-23 |
| Identifying Sleep Apnea Patients That Best Respond to Atomoxetine Plus Oxybutynin Therapy Atomoxetine, Oxybutynin - Obstructive Sleep Apnea | Phase 1 / Phase 2 | Unknown | Brigham and Women's Hospital | 22 | 2022-05-05 | 2023-10-18 |
| Trial of AD113 and Atomoxetine in OSA Patients With Hypertension AD113, Atomoxetine - Obstructive Sleep Apnea, Hypertension | Phase 2 | Completed | Apnimed | 21 | 2021-07-31 | 2023-08-21 |
| Enhancing the Effects of Adolescent Alcohol Treatment With Atomoxetine Atomoxetine, Placebo - Alcohol Use Disorder | Phase 2 | Completed | Brown University | 42 | 2021-05-06 | 2025-05-09 |
| Crossover Trial of AD109 in Obstructive Sleep Apnea AD109, Atomoxetine, R-oxybutynin - Obstructive Sleep Apnea | Phase 2 | Completed | Apnimed | 60 | 2020-10-27 | 2023-01-31 |
| Crossover Trial of AD036 in Obstructive Sleep Apnea AD036, Atomoxetine, Placebo - Obstructive Sleep Apnea | Phase 2 | Completed | Apnimed | 62 | 2020-07-15 | 2023-09-14 |
| A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine Methylphenidate, Lisdexamfetamine, Atomoxetine - Attention Deficit Disorder With Hyperactivity | Completed | Janssen Research & Development, LLC | 430000 | 2019-10-09 | 2025-06-25 | |
| A Novel Pharmacological Therapy for Obstructive Sleep Apnea Atomoxetine, Oxybutynin, Placebo - Sleep Apnea | Phase 2 | Completed | Brigham and Women's Hospital | 117 | 2019-09-03 | 2026-07-02 |
| The Neuroprotective Effects of Methylphenidate and Atomoxetine in Children With ADHD: A Lipidomic Study Methylphenidate, Atomoxetine - Attention Deficit Hyperactivity Disorder | Not applicable | Completed | National Taiwan University Hospital | 105 | 2019-08-01 | 2024-04-16 |
| Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk Methylphenidate, Atomoxetine - ADHD, Attention Deficit Hyperactivity Disorder | Phase 4 | Unknown | Icahn School of Medicine at Mount Sinai | 44 | 2019-06-04 | 2024-08-09 |
| Role of Coenzyme Q in ADHD in Children Atomoxetine, Coenzyme Q - ADHD | Phase 3 | Recruiting | Sherief Abd-Elsalam | 40 | 2018-11-01 | 2020-01-02 |
Showing 20 of 127. Sign in to see all of them.
Attention Deficit Disorder with Hyperactivity (74) · Parkinson Disease (6) · Schizophrenia (5) · Substance-Related Disorders (5) · Marijuana Abuse (4) · Sleep Apnea, Obstructive (4) · Autistic Disorder (3) · Cognitive Dysfunction (3) · Dyslexia (3) · Memory Disorders (3) · Behavior, Addictive (2) · Cocaine-Related Disorders (2) · Cognition Disorders (2) · Depression (2) · Hypotension, Orthostatic (2)
Eli Lilly and Company (31) · Yale University (5) · Icahn School of Medicine at Mount Sinai (4) · Apnimed (3) · Brigham and Women's Hospital (3) · Massachusetts General Hospital (3) · Medical University of South Carolina (2) · National Institute on Drug Abuse (NIDA) (2) · New York State Psychiatric Institute (2) · Peking University (2) · Pfizer (2) · Rhode Island Hospital (2) · University of Maryland, Baltimore (2) · University of Pennsylvania (2) · University of Turku (2)
United States (69) · Germany (9) · South Korea (8) · Netherlands (6) · United Kingdom (6) · Canada (5) · France (5) · Japan (5) · Taiwan (5) · Belgium (4) · China (4) · Italy (4) · Sweden (4) · Finland (3) · Norway (3)
Mehmet Sofuoglu, M.D., Ph.D. (3) · Scott A Sands, PhD (3) · Satish R Raj, MD MSCI (2) · Abeer Salamah, Lecturer (1) · Aimee L McRae, PharmD (1) · Albert Arias, MD (1) · Alison Oliveto, PhD (1) · Allan I. Levey, MD, PhD (1) · Andreas Karwautz, Prof (1) · Ashley H Shoemaker, MD, MSCI (1) · Benjamin Handen, PhD (1) · Boong-nyun Kim, MD, PhD (1)
PMID 25019647, PMID 37811711, PMID 21432592, PMID 21569378, PMID 10662747, PMID 11904109, PMID 11927799, PMID 12119802, PMID 12832331, PMID 15066944, PMID 15710782, PMID 15738343, PMID 15911704, PMID 17242628, PMID 17388708, PMID 17515447, PMID 17515448, PMID 18182254, PMID 19025777, PMID 19358788, PMID 19687359, PMID 19703299, PMID 19910721, PMID 20003507, PMID 20035590, PMID 20377705, PMID 20494267, PMID 20673557, PMID 20679638, PMID 20837887, PMID 21156272, PMID 21265936, PMID 21356232, PMID 21422081, PMID 22017969, PMID 22029549, PMID 22311903, PMID 22313788, PMID 22721596, PMID 22987022, PMID 23578015, PMID 23648011, PMID 24002370, PMID 24018545, PMID 24206099, PMID 24227635, PMID 24495468, PMID 24606242, PMID 24705867, PMID 24721800
2019 (2), 2009 (1), I01RX004823 (1), K02DA021304 (1), K23MH066127 (1), K23MH067894 (1), K24AA000301 (1), K24AA026326 (1), K24DA016264 (1), P50DA009236 (1), P50NS062684 (1), P60DA005186 (1), R01DA019233 (1), R01DA022191 (1), R01DK142434 (1)